Aggregated price index with volume information
Summary:
- Medical Laboratories stocks up 3.7% on average while median return up 0.6% in a day
- Medical Laboratories stocks down 0.6% on average while median return down 0.4% in a week
- Medical Laboratories stocks up 28.6% on average while median return up 11.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $PSNL 189.9%, $CDNA 35.7%, $CELC 16.8%
- 1M losers are : Losers for past month are $NTRA -7.8%, $WST -12.0%
- 1W winners are : Winners for past week are $CELC 8.4%, $CDNA 5.1%, $VCYT 2.3%
- 1W losers are : Losers for past week are $NTRA -3.1%, $PSNL -10.4%, $WST -10.4%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 9.2%, for the past 3 months is 10.0%
In the past month for a 5 days rolling window, the highest corrrelation is 26.3%, the lowest correlation is -9.4%, the latest correlation is -3.1%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 72.8% between CDNA and VCYT
The lowest correlation is -42.4% between CELC and PSNL
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
West Pharmaceutical (WST) delivered earnings and revenue surprises of -14.12% and 4.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Exton, Pennsylvania-based company said it had profit of $1.51. Earnings, adjusted for amortization costs, were $1.52 per share. The results missed Wall Street expectations.
West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance.
FREMONT, Calif., July 24, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
This month, we saw the Personalis, Inc. ( NASDAQ:PSNL ) up an impressive 94%. But only the myopic could ignore the...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund’s Investor Class fund ARTMX returned -5.73%, Advisor Class fund APDMX posted a return of -5.67%, and Institutional Class fund APHMX returned -5.64%, compared […]
BRISBANE, Calif., July 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.